Podcast with global experts discussing the role of AKT and PI3K inhibitors in patients with resistance to endocrine therapy in the adjuvant or metastatic disease settings following current guidelines, indications, and best clinical practices. Presenters: Nadia Harbeck, MD Breast Cancer Director Department of OB&GYN and Comprehensive Cancer Center Munich LMU University Hospital Munich, Germany Francois-Clement Bidard, MD, PhD Breast Medical Oncology Institut Curie & University of Versailles Paris, France Link to full program:https://bit.ly/4cFd0Xj Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related